🇺🇸 Rifaximine in United States

40 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 6 reports (15%)
  2. Diarrhoea — 5 reports (12.5%)
  3. Hepatic Failure — 5 reports (12.5%)
  4. Drug Resistance — 4 reports (10%)
  5. Encephalopathy — 4 reports (10%)
  6. Hepatic Encephalopathy — 4 reports (10%)
  7. Glomerular Filtration Rate Decreased — 3 reports (7.5%)
  8. Hepatitis C — 3 reports (7.5%)
  9. Pyrexia — 3 reports (7.5%)
  10. Septic Shock — 3 reports (7.5%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Rifaximine approved in United States?

Rifaximine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Rifaximine in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.